Related Experiment Videos
Targeting the central nervous system inflammatory response in ischemic stroke
1Department of Neurology, University of Washington School of Medicine, Seattle, Washington, USA. kjb@u.washington.edu
Current Opinion in Neurology
|May 24, 2001
Summary
Inflammation contributes to ischemic stroke injury in models, but clinical trials targeting this response have failed. These failures may stem from insufficient preclinical data and poor trial design, not a lack of inflammation
Area of Science:
- Neuroscience
- Immunology
- Cerebrovascular disease
Background:
- Inflammation plays a role in cerebral ischemic injury in experimental stroke models.
- Clinical trials targeting post-ischemic inflammation have yielded disappointing results.
- The efficacy of anti-inflammatory strategies in stroke remains uncertain.
Purpose of the Study:
- To evaluate the role of inflammation in cerebral ischemic injury.
- To analyze the reasons for the failure of clinical trials targeting post-ischemic inflammation.
- To guide future research and clinical trial design for stroke treatment.
Main Methods:
- Review of experimental models of stroke.
- Analysis of clinical trial data for anti-inflammatory therapies.
- Assessment of preclinical data supporting inflammation's role.
Main Results:
- Experimental models consistently show inflammation contributes to ischemic brain damage.
- Clinical trials have not successfully translated these findings into effective treatments.
- Potential reasons for clinical failure include insufficient preclinical evidence and inadequate trial design.
Conclusions:
- Inflammation is implicated in ischemic stroke injury, supported by preclinical data.
- Clinical trial failures suggest issues with study design and data, not necessarily the absence of inflammation's role.
- Further well-designed studies are needed to explore anti-inflammatory treatments for stroke.